Dr. Jedd D. Wolchok is the Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation; Chief, Immuno-Oncology Service, Human Oncology and Pathogenesis Program; director, Parker Institute for Cancer Immunotherapy; and associate director, the Ludwig Center for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center.
Dr. Wolchok has been at the forefront of cancer immunotherapy and is renowned for leading the clinical trials that led to the first FDA-approved checkpoint inhibitor immunotherapy, the anti-CTLA-4 antibody ipilimumab. He continues to lead clinical trials aimed at expanding immunotherapy’s benefits to more patients. He also conducts research that focuses on the GITR and OX40 pathways, as well as how some immune cells, known as myeloid-derived suppressor cells, influence anti-tumor immune responses.
In addition to his role as an associate director of CRI’s Scientific Advisory Council, Dr. Wolchok serves on the CLIP Grant Review Committee and is also a member of CRI’s Clinical Leadership Committee.
People come to us for the possibility of a new and better treatment option, and that's what we believe clinical trials offer.
¡Hagamos correr la voz sobre la inmunoterapia! Haga clic para compartir esta página con su comunidad.